Adverse Drug Events (1) Atorvastatin (4) Cannabis (7) Clozapine (9) Cyclosporine* (10) Empagliflozin* (2) Fenofibrate (13) Gadolinium-Based Contrast Agents A 75-year-old man developed dysuria, polyuria, chills, lower extremity weakness, and flank pain approximately 2 months after initiating empagliflozin (25 mg orally daily) for type 2 diabetes mellitus. Concurrent medications included metformin extended-release (1000 mg orally daily), allopurinol (100 mg orally daily), chewable aspirin (81 mg daily), and moexipril-hydrochlorothiazide (15-25 mg orally daily). Physical examination revealed fever (38.8°C), hypotension (83/60 mm Hg), tachycardia (heart rate 110 beats/min), and tachypnea (25 respirations/min). Initial treatment included administration of normal saline (2 L bolus) and ceftriaxone (1 g intravenously). Heart rate and blood pressure initially improved (86 beats/min and 118/70 mm Hg, respectively); however, 1 hour later blood pressure and heart rate dropped. Hypotension persisted (systolic blood pressure in the 80s and mean arterial pressure less than 60). Additional treatment included admission to the intensive care unit, administration of maintenance fluids (125 mL/h), norepinephrine (15 mg/min), and piperacillin-tazobactam (3.375 g intravenously every 8 hours), and discontinuation of moexipril-hydrochlorothiazide, empagliflozin, and metformin. Blood sugars were controlled with insulin lispro sliding scale. Serum laboratory analysis revealed hyperglycemia (blood glucose, 153 mg/dL), a hemoglobin A1C of 7.1%, negative b-hydroxybutyrate (0.31 ng/mL), acute kidney injury (serum creatinine, 1.9 mg/dL, and blood urea nitrogen, 30 mg/dL), elevated anion gap (21 mmol/L), low bicarbonate (16 mmol/L), leukocytosis (white blood cell count, 13.5), and elevated procalcitonin (50.89 ng/mL) and lactic acid (2.0 mmol/L). Urinalysis was indicative of urinary tract infection (hemoglobin 2+, ketones 20, leukocyte esterase 2+, red blood cells 11, pH 5.0, specific gravity 1.004, total protein 30, and white blood cells 125) and was positive for glycosuria (glucose > 500). Urine and blood cultures grew Serratia marcescens, and ciprofloxacin (400 mg intravenously every 12 hours) was initiated. Repeat blood cultures were negative, and by day 3, leukocytosis and acute kidney injury were resolved. On day 5 of hospitalization, discharge occurred, and oral ciprofloxacin (500 mg every 12 hours) was continued for a total 14-day course. Empagliflozin was not restarted. At follow-up through 4 months, repeat urine cultures were negative, and no urinary symptoms were present.
The authors concluded that this case described the first report of pyelonephritis related to empagliflozin administration. The authors reported a probable association with empagliflozin as assessed via the Naranjo Adverse Drug Reaction Probability Scale. The proposed mechanism was empagliflozin-induced glycosuria.
Empagliflozin 
ATORVASTATIN

No. 4 Rhabdomyolysis
A 91-year-old male developed muscle weakness, pain, unexplained soreness, and falls approximately 4 months after initiating atorvastatin (40 mg daily decreased from 80 mg daily 10 days prior) following myocardial infarction. Concurrent medications included oral furosemide (40 mg every morning and 20 mg every evening), lisinopril (10 mg daily), pantoprazole (40 mg daily), clopidogrel (75 mg daily), aspirin (81 mg daily), metoprolol succinate (25 mg once daily), nitroglycerin (0.4 mg sublingual tablets as needed for angina), potassium chloride (20 mEq in the morning and 10 mEq in the afternoon), and an ophthalmic multivitamin (twice daily). Significant vital signs on admission included hypotension (blood pressure, 92/54 mm Hg). Significant laboratory findings included serum creatine phosphokinase (18 723 units/L), blood urea nitrogen (72 mg/dL), serum creatinine (1.6 mg/dL increased from baseline 0.95 mg/dL), alkaline phosphatase (197 units/L), aspartate aminotransferase (567 units/L), alanine aminotransferase (190 units/L), total bilirubin (2.1 mg/dL), and direct bilirubin (0.6 mg/dL). Urinalysis revealed cloudy yellow urine with hyaline casts (21), urobilinogen (2.0 EU/dL), moderate amounts of blood and mucus, 1 red blood cell per high-power field, specific gravity of 1.014, pH of 5.0, and negative for glucose, bilirubin, ketones, protein, nitrite, leukocytes, white blood cell casts, red blood cell casts, granular casts, yeast, and bacteria. Treatment included discontinuation of atorvastatin and administration of normal saline (500 mL infused at a rate of 100 mL/h twice). Symptoms of pain and muscle weakness improved, and discharge occurred on day 4. At the time of discharge, repeat laboratory analysis revealed improved laboratory parameters including serum creatine phosphokinase (5908 units/L), blood urea nitrogen (64 mg/dL), serum creatinine (1.3 mg/dL), alkaline phosphatase (171 units/L), aspartate aminotransferase (320 units/L), and alanine aminotransferase (139 units/L). Twenty-two days after discharge, laboratory parameters continued to improve including serum creatine phosphokinase (161 units/L), blood urea nitrogen (36 mg/dL), serum creatinine (1.64 mg/dL), alkaline phosphatase (168 units/L), aspartate aminotransferase (62 units/L), and alanine aminotransferase (36 units/L). Statin therapy was not reinstated.
The authors concluded that this case of rhabdomyolysis had a probable association with administration of atorvastatin as assessed via the Naranjo Probability Scale. Proposed mechanisms included atorvastatininduced inactivation of guanosine triphosphate hydrolases resulting in mitochondrial dysfunction and adenosine triphosphate depletion.
Atorvastatin 
NILOTINIB
No. 5 FDA News Release: Instructions for Discontinuation
On December 22, 2017, the US Food and Drug Administration announced changes to labeling for nilotinib regarding specific instructions for the discontinuation in certain patient populations who have achieved sustained response. These instructions were based on data from 2 single-arm trials in patients with Ph+ chronic myeloid leukemia.
Nilotinib 
TRIMETHOPRIM-SULFAMETHOXAZOLE No. 6 Hemolytic Anemia
A 47-year-old woman developed yellowing of the skin and eyes, lethargy, abdominal pain, and dry mucus membranes after receiving 3 doses of trimethoprim-sulfamethoxazole (800 mg/160 mg orally twice daily) for treatment of a urinary tract infection. Concurrent medications included insulin glargine and insulin lispro. Initial treatment included discontinuation of trimethoprim-sulfamethoxazole, and antimicrobial therapy was continued with ciprofloxacin (250 mg orally twice daily). However, symptoms of lightheadedness developed, and emergency department evaluation was required. Significant laboratory findings included red blood cells of 1.99 m/mm3, hemoglobin of 6.3 g/dL, hematocrit of 18.1%, elevated total bilirubin (6.7 mg/dL), aspartate aminotransferase (51 IU/L), blood urea nitrogen (23 mg/dL), and lactate dehydrogenase (1214 IU/L), and normal alanine aminotransferase, alkaline phosphatase, international normalized ratio, platelet count, and serum creatinine. Laboratory tests for infectious etiology including hepatitis A, B, and C, as well as urine culture and urinalysis were negative. Immunohematology studies revealed positive antibody screening test, warm antibodies with no alloantibodies present, and positive direct antiglobulin test revealed 2+ antihuman globulin, 1+ anti-IgG, and negative anti-C3. A repeat on day 7 confirmed results. Initial treatment included administration of intravenous methylprednisolone (60 mg once) that was transitioned to oral prednisone (60 mg daily) and folic acid (1 mg twice daily) the following day. Two days later, hemoglobin and hematocrit continued to decline (4.2 mg/dL and 12.6%, respectively); however, total bilirubin improved (3.2 mg/dL). Additional treatment included transfusion of packed red blood cells (1 unit on days 3 and 4 of admission). On the sixth day of admission, hemoglobin, hematocrit, and bilirubin had improved (5.3 mg/dL, 16.5%, and 2.9 mg/dL, respectively). Pantoprazole (40 mg by mouth daily) was initiated for stomach cramps. On day 8, hemoglobin and hematocrit again declined (4.8 mg/dL and 15.6%, respectively), and lactate dehydrogenase was 963 mg/dL. One additional unit of packed red blood cells was administered. Hemoglobin and hematocrit remained stable over the subsequent 2 days (6.4 mg/dL and 19.7%, respectively). Discharge was performed the following day with prednisone (60 mg daily), pantoprazole (40 mg daily), and folic acid (1 mg twice daily), and home insulin regimen was restarted. Hemoglobin and hematocrit continued to improve, and prednisone was slowly tapered over the following month. Hemoglobin and hematocrit remained stable at 11.0 mg/dL and 32.7%, respectively, following cessation of prednisone.
The authors concluded that this case described a probable case of drug-induced autoimmune hemolytic anemia related to trimethoprim-sulfamethoxazole as assessed via the Naranjo Adverse Drug Reaction Probability Scale (score 7). Proposed mechanisms were not discussed.
Trimethoprim 
CANNABIS
No. 7 Cannabinoid Hyperemesis Syndrome
A series of 19 clinical cases of cannabinoid hyperemesis syndrome in France were reported. The average amount of cannabis consumed was 10 joints per day. Concurrent substance use included nicotine (all cases), alcohol (4 cases), and other illicit drugs (2 cases). Concurrent therapeutic treatments included antidepressant, neuroleptic, and anxiolytic (3 cases) medications. All cases had a history of substance use disorder. The majority of cases (n = 16) were males aged 20 to 48 years (mean = 29.8 years). Median time to onset of symptoms from first use was 9 years (range = 3-25 years). Median time to onset of symptoms from time of first regular use, defined as more than 10 consumptions in the last month, was 5 years (range = 3-23 years). Average time from onset of symptoms to diagnosis of cannabinoid hyperemesis syndrome was 2.6 years (range = 1 day to 9 years). Symptoms included vomiting and abdominal pain in all cases. Weight loss of greater than 5 kg occurred in 12 cases. Hot shower had a positive association on vomiting in 17 cases and on pain in 13 cases; however, there was an inconsistent response in 2 cases. Ninety-nine percent of cases consulted emergency department services for symptoms related to cannabinoid hyperemesis syndrome at least once. Treatment included administration of antiemetics, antispasmodics, anxiolytics, and pain medications. Morphine was administered in 5 cases, and relief was reported as inconsistent. Recovery usually required discontinuation of cannabis.
The authors concluded that these cases described cannabinoid hyperemesis syndrome. Proposed mechanisms included dysregulation of the endocannabinoid system, desensitization of the endocannabinoid system, chronic accumulation of lipophilic cannabinoids in brain and fatty tissues, and a genetic variation in metabolism.
Cannabis 
GADOLINIUM-BASED CONTRAST AGENTS No. 8 FDA Safety Communication: Prolonged Residual Body Storage
On December 19, 2017, the US Food and Drug Administration announced that they are requiring a new class warning and other safety measures for all gadolinium-based contrast agents. Specifically, the statement continues an earlier advisory that noted that gadolinium has prolonged residual storage in the body, including the brain. The statement also noted that gadolinium retention has not been directly associated with adverse effects in patients with normal kidney function and that the benefit-risk ratio of these drugs remains favorable to use. The most recent safety communication has alerted clinicians regarding actions that may minimize issues associated with retention. In addition, the manufacturers of these agents will be required to conduct both human and animal studies to further assess the safety profile. It was noted in the statement that linear gadolinium-based contrast agents result in more retention and retention for a longer time than macrocyclic agents.
Gadolinium-Based Contrast Agents ["Omniscan," "OptiMARK," "Eovist," "Magnevist," "MultiHance," "Dotarem," "Gadavist," "ProHance"] FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm (Dec 19) 2017 No. 9 6
CLOZAPINE
No. 9 Cardiotoxicity
A retrospective study was performed to evaluate cardiac effects in 27 hospitalized patients receiving clozapine and 12 hospitalized patients receiving alternative antipsychotic agents for treatment-resistant schizophrenia that were referred for cardiology evaluation. Mean age was 46 ± 13 years, and 31% (n = 12) were women. The most frequent indication for cardiology referral was tachycardia (59%). Of the clozapine-treated patients, median left ventricular ejection fraction was 52% (interquartile range = 44-55), and median heart rate was 98 bpm (interquartile range = 85-114). A significant association was not observed between age and left ventricular ejection fraction, QRS duration, heart rate, or QTc interval. Additionally, no significant association was observed between duration of clozapine treatment and left ventricular ejection fraction or QRS duration. A total of 16 (59%) patients on clozapine were referred for cardiology due to the development of tachycardia (mean heart rate = 103 bpm; interquartile range = 94-116). This was sinus tachycardia in all cases, and no arrhythmias were documented. No significant effect was observed between time on clozapine and heart rate (P = .15) or QTc interval (P = .16). Treatment included b-blockers (n = 5) and ivabradine (n = 2); however, a significant difference in heart rate was not observed between those treated with rate controlling medication (101 ± 10 bpm) and those that were not (110 ± 14 bpm; P = .22). Four patients discontinued clozapine at follow-up due to neutropenia (n = 1), poor compliance (n = 1), and patient choice (n = 2). Eleven patients treated with clozapine were referred to cardiology due to possible heart failure/myocarditis. The median left ventricular ejection fraction in this group was 38% (interquartile range = 36-52), QRS duration and QTc were normal, and there was no significant relationship between time on clozapine and ejection fraction (r = -0.1; P = .78). There was no significant difference in age, sex, QRS duration, or QTc interval in patients on clozapine that did and did not develop tachycardia or symptoms of heart failure. Heart rate was significantly higher in the clozapine patients with tachycardia (103 bpm vs 83 bpm; P = .002), and left ventricular ejection fraction was significantly lower in the clozapine cardiomyopathy group (38% vs 55%; P < .001). Clozapine was discontinued sooner in patients on clozapine with cardiomyopathy than those with tachycardia (median time = 0.3 vs 2.3 years; P = .065). Clozapine patients referred for cardiology evaluation were younger than those on other antipsychotic medications (44 ± 13 years vs 56 ± 9 years; P = .02); however, there were no significant differences between the 2 groups with regard to length of time on drug at review (P = .35), left ventricular ejection fraction, heart rate, QRS duration, or QTc interval. Serial echocardiograms were performed in 7 patients treated with clozapine and revealed that in patients with left ventricular dysfunction, no decline in left ventricular function occurred over a 4-month period. Patients on antipsychotics other than clozapine were more likely to experience deterioration in ejection fraction during treatment (86% vs 14%; P = .004).
The authors concluded that results of this study suggested that clozapine use was safe and was not associated with significant morbidity or mortality. They further stated that misconceptions and lack of specialist knowledge may contribute to early termination of clozapine and fears related to side effects that are often benign.
Clozapine A 58-year-old Chinese man developed gum bleeding, bright red blood mixed with stool, nausea, and vomiting 8 days after initiating ticagrelor (90 mg twice daily) for treatment of acute coronary syndrome while receiving cyclosporine (200 mg daily) for renal transplant. Prior antiplatelet therapy included a loading dose of aspirin (300 mg) and ticagrelor (180 mg) 8 days prior, at the time of acute coronary syndrome with coronary angiography and percutaneous coronary intervention. Concurrent medications included mycophenolate mofetil (2 g daily), aspirin (100 mg daily), atorvastatin (20 mg daily), and olmesartan (20 mg daily). Physical examination revealed a decline in blood pressure (125/88 to 98/68 mm Hg) and an increase in heart rate (77-81 beats/min to 101-110 beats/min). Initial treatment included discontinuation of olmesartan and administration of intravenous pantoprazole (80 mg daily). The following day, bloody stools continued with a maximum of 250 to 350 mL every 20 minutes. Significant laboratory findings included a decline in hemoglobin (baseline 9.9 g/dL to 4.6 g/dL). Further treatment included discontinuation of ticagrelor and administration of intravenous pantoprazole (80 mg twice daily), agkistrodon snake venom hemocoagulase (2 units daily), and norepinephrine (2 mg daily via nasogastric feeding tube). Packed red blood cells (10 units total) and plasma (600 mL total) were continuously transfused. Gastroscopic and enteroscopic examination did not reveal the location of gastrointestinal hemorrhage. Five days later, the bleeding was well controlled, and hemoglobin gradually increased (7.8 g/dL, 8.0 g/dL, 8/0 g/dL, and 8.9 g/dL). Ticagrelor was replaced with clopidogrel (75 mg daily).
The authors concluded that the life-threatening bleeding described in this case was probably related to ticagrelor therapy as assessed via the Naranjo Adverse Drug Reaction Probability Scale (score 7). They further stated that this was the first report of ticagrelor-induced serious bleeding in a renal transplant patient due to a potential drug-drug interaction with cyclosporine. The proposed mechanism was increased ticagrelor serum concentrations induced by cyclosporine-mediated inhibition of P-glycoprotein.
Cyclosporine ["Gengraf," "Neoral, On December 18, 2017, the US Food and Drug Administration (FDA) announced a new, risk-based enforcement approach to the evaluation of homeopathic products. The announcement noted that though homeopathic drug products are subject to the same legal requirements related to approval, adulteration and misbranding as any other drug product, homeopathic products are distributed without FDA approval. Thus, the benefit-risk ratio is not established. The new process will be focused on labeled homeopathics that have the greatest potential to cause risk to patients. Products that have been identified as potential initial candidates for enforcement priorities are infant and children's products containing ingredients associated with potentially significant safety concerns (eg, belladonna, nux vomica) and products marketed for serious conditions.
Homeopathics 
GSK2793660
No. 12 Epidermal Desquamation
In a crossover trial, 33 healthy male subjects were randomized to receive single escalating oral doses of GSK2793660 (0.5 mg, 2 mg, 6 mg, 12 mg, 20 mg) or placebo. In a separate cohort trial, the male subjects received once daily doses of GSK2793660 (12 mg) or placebo for 21 days. Data collected included parameters to measure safety, pharmacokinetics, and blood biomarkers. Dose-dependent activity was noted in both trials. A total of 9 adverse events occurred in 6 subjects during the first study. Five events were reported with placebo and 4 events were associated with GSK2793660. The only treatment-related effects were thought to be dizziness. In the second trial, 7 of the 10 subjects receiving repeat doses of GSK2793660 developed mild epidermal desquamation on palmar and plantar surfaces. The onset of the reaction was 7 to 10 days after initiation of 12 mg once daily dosing. The study was stopped based on predetermined criteria for safety events.
The authors concluded that repeated dosing of GSK2793660 was associated with epidermal desquamation on palmar and plantar surfaces. These data will be significant in determining the future research on the benefit risk ratio of therapy with these type of agents.
GSK2793660 
FENOFIBRATE
No. 13 Drug-Induced Liver Injury
In a retrospective review of the Drug-Induced Liver Injury Network, 1229 patients with definite, very likely, and probable drug-induced liver injury between 2004 and 2015 were identified. Of these reports, 7 cases (0.6%) were associated with the use of fenofibrate. The median age of the patients was 43 years (range = 37-61 years). Time to onset was 5 to 8 weeks in 4 patients but more prolonged (18-56 weeks) in the remaining 3 patients. The majority of the cases developed jaundice (n = 6). Laboratory results included hepatocellular, mixed, and cholestatic injury. Four of the patients required hospitalization and 2 in whom drug discontinuation was delayed had a severe outcome, 1 undergoing liver transplantation and 1 developing chronic injury and death. When causality was assessed, it was considered highly likely in 5 patients and probable in 2 patients.
Based on the results of this evaluation, the authors concluded that fenofibrate has been associated with liver injury but that though most cases are self-limited, the potential for severe injury and mortality is possible.
Fenofibrate 
